Table 1 Baseline characteristics
Characteristics | Total population (N = 334) |
|---|---|
Age, median (range), y | 68 (22–89) |
Sex, n (%) | |
Men | 250 (75) |
Women | 84 (25) |
Tumor histology, n (%) | |
Clear cell | 293 (88) |
Non–clear cell | 24 (7) |
Missing | 17 (5) |
KPS, median (range) | 80 (50–100) |
Time since diagnosis, median (range), y | |
Initial | 3.3 (0–34) |
Metastasis | 1.7 (0–16) |
MSKCC risk status at start of first-line therapy, n (%)a | |
Favorable | 84 (35) |
Intermediate | 134 (56) |
Poor | 20 (8) |
Primary metastatic site, n (%)b | |
Lung | 226 (68) |
Lymph node | 145 (43) |
Skeletal system | 125 (37) |
Liver | 87 (26) |
Adrenal gland | 47 (14) |
Previous surgery, n (%) | 325 (97) |
Previous nephrectomy | 300 (90) |
Number of previous antineoplastic therapies, n (%) | |
1 | 240 (72) |
2 | 69 (21) |
≥3 | 25 (7) |